Paper Details

  1. Home
  2. Paper Details

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.

Author: AwDerrick Chen-Wee, BaoWeibin, DeeCathleen Michelle A, GuanaAdriana, HuangYu-Huei, KimTae-Gyun, LeeJoo-Heung, LeeMin-Geol, LeeSeung-Chul, TsaiTsen-Fang

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study examined the effectiveness of secukinumab, a drug used to treat psoriasis, in Asian patients with moderate to severe psoriasis. The study found that secukinumab was highly effective and well-tolerated in this population.
Paper Details　
Original Abstract of the Article :
The 52-week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient-reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/1346-8138.15004

データ提供：米国国立医学図書館（NLM）

Secukinumab: A Faster Route to Clear Skin in Asian Patients with Psoriasis

The quest for effective treatments for [psoriasis] is ongoing. This study focuses on comparing the efficacy of [secukinumab] and [ustekinumab] in Asian patients with moderate to severe plaque psoriasis. It's like exploring different paths in a vast desert, seeking the quickest and most effective route to clear skin.

Secukinumab Shows Superior Efficacy in Asian Patients

This subgroup analysis of the CLEAR study found that secukinumab demonstrated superior efficacy and a faster response in clearing skin compared to ustekinumab in Asian patients. This is like finding a shortcut through the desert, leading to a quicker and more successful journey to clear skin.

Hope for Asian Psoriasis Patients

The study provides encouraging news for Asian patients with psoriasis. It highlights the potential of secukinumab to offer faster and more effective skin clearing compared to ustekinumab. It's like discovering a hidden oasis that provides a refreshing solution for this condition.

Dr.Camel's Conclusion

This research offers a promising oasis in the desert of psoriasis, demonstrating the superior efficacy of secukinumab in achieving clear skin for Asian patients. It's a step towards finding more personalized and effective treatments for this challenging condition.

Date :
  1. Date Completed 2019-11-13
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

31342560

DOI: Digital Object Identifier

10.1111/1346-8138.15004

Related Literature

Article Analysis
・Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.